- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07606638
Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients
This randomized clinical study was designed to compare two pain treatment approaches for adults with oral cancer who had moderate to severe pain. Oral cancer pain may occur because of tumor growth, local tissue damage, inflammation, ulceration, or nerve involvement. Standard pain treatment often includes opioid medicines, but these medicines may cause side effects such as sedation, nausea, constipation, dizziness, tolerance, or dependence. In some patients, pain may also have a nerve-related or inflammatory component, where medicines such as pregabalin and naproxen sodium may provide additional benefit.
A total of 98 eligible adult patients with histopathology-confirmed oral cancer and a baseline Visual Analog Scale pain score of 4 or more were included. Patients were randomly assigned into two treatment groups. One group received oral tramadol 50 mg every 4 hours, with dose adjustment according to pain relief and tolerability. The other group received oral pregabalin 75 mg twice daily with naproxen sodium 550 mg twice daily. Both treatments were given for 7 days under clinical monitoring.
Pain intensity was measured using the Visual Analog Scale at baseline, day 3, and day 7. The main outcome was the mean reduction in pain score from baseline to day 7. Effective pain relief was defined as at least 50% reduction in the baseline pain score after 7 days of treatment. Side effects such as sedation, nausea or vomiting, constipation, dizziness, and gastrointestinal discomfort were also recorded. Patient satisfaction with pain control was assessed at the end of treatment.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Mayo Hospital, Lahore
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Patients aged 18 years or older
- Histopathology confirmed diagnosis of oral cancer
- Experiencing moderate to severe pain (VAS ≥ 4)
- Either opioid-naïve or off opioids for at least one week
- Able to provide informed consent
Exclusion Criteria:
- Known allergy to morphine, pregabalin, or NSAIDs
- History of renal impairment, gastrointestinal bleeding, or peptic ulcer disease
- Concurrent use of other strong analgesics
- Psychiatric illness or cognitive impairment interfering with pain assessment
- Pregnancy or lactation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Group A Tramadol
Received oral tramadol 50 mg every 4 hours for pain management.
Dose titration was done according to pain relief and tolerability.
Treatment was continued for 7 days with clinical monitoring for pain response and adverse effects.
|
Oral tramadol 50 mg was administered every 4 hours for 7 days.
Dose adjustment was made according to clinical response and tolerability.
|
|
Sperimentale: Group B Pregabalin Plus Naproxen Sodium
Received oral pregabalin 75 mg twice daily along with oral naproxen sodium 550 mg twice daily for pain management.
Treatment was continued for 7 days with clinical monitoring for pain response and adverse effects.
|
Oral pregabalin 75 mg was administered twice daily for 7 days.
Oral naproxen sodium 550 mg was administered twice daily for 7 days.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Change in Visual Analog Scale Pain Score From Baseline to Day 7
Lasso di tempo: Baseline and Day 7
|
Pain intensity was assessed using the Visual Analog Scale, ranging from 0 to 10, where 0 indicated no pain and 10 indicated the worst imaginable pain.
The mean change in pain score was calculated by subtracting the day 7 Visual Analog Scale score from the baseline Visual Analog Scale score.
A greater positive change indicated greater reduction in pain intensity.
The mean change was compared between the tramadol group and the pregabalin plus naproxen sodium group.
|
Baseline and Day 7
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Effective Pain Relief at Day 7
Lasso di tempo: Baseline to Day 7
|
Effective pain relief was defined as at least 50% reduction in the baseline Visual Analog Scale pain score after 7 days of treatment.
The proportion of participants achieving effective pain relief was compared between the two treatment groups.
|
Baseline to Day 7
|
|
Severity of Adverse Events
Lasso di tempo: Day 0 to Day 7
|
The severity of adverse events was assessed using the Common Terminology Criteria for Adverse Events version 5.0.
Events were categorized according to severity grade and compared between the treatment groups.
|
Day 0 to Day 7
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Rooshan Tahir Qazi, Mayo Hospital Lahore
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie della bocca
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Carcinoma, cellule squamose
- Carcinoma a cellule squamose della testa e del collo
- Neoplasie della bocca
- Aminoacidi, peptidi e proteine
- Prodotti chimici organici
- Lipidi
- Idrocarburi
- Idrocarburi, ciclici
- Acidi, aciclici
- Acidi carbossilici
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Ammine
- Aminoacidi
- Alcoli
- acido gamma-aminobutirrico
- Aminobutyrites
- Butirati
- Ciclohexanoli
- Esanoli
- Alcoli grassi
- Dimetilammine
- Metilammine
- Acidi naftaleneacetici
- Pregabalin
- Tramadolo
- Naprossene
Altri numeri di identificazione dello studio
- Mayo6
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .